FDA: Ceftriaxone Must Not Be Co-administered with Calcium

"Rocephin (Ceftriaxone sodium), Contraindications, Warnings, Precautions, Adverse Reactions, Dosage and Administration Sections of Labeling Revised"

BETHTESA, MD -- July 6, 2007 -- Roche and FDA informed healthcare professionals of revisions to the prescribing information for Ceftriaxone for injection. Concomitant use of ceftriaxone with calcium or calcium containing solutions can rarely cause fatal reactions with calcium-ceftriaxone precipitates in the lungs and kidneys in both term and premature neonates. Hyperbilirubinemic neonates, especially prematures, should not be treated with Ceftriaxone. The drug must not be mixed or administered simultaneously with calcium-containing solutions or products, even via different infusion lines. Additionally, calcium-containing solutions or products must not be administered within 48-hours of the last administration of ceftriaxone.